Effectiveness of pharmaceutical smoking cessation AIDS in a nationally representative cohort of American smokers

Journal of the National Cancer Institute

Volumn 110, Issue 6, 2018, Pages 581-587

  Leas, Eric C ^a,b,d   Pierce, John P ^a,d   Benmarhnia, Tarik ^a,c,d   White, Martha M ^a,d   Noble, Madison L ^a,d   Trinidad, Dennis R ^a,d   Strong, David R ^a,d  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c San Diego   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; NICOTINE; VARENICLINE;

ABSTINENCE; ADULT; AMERICAN; ARTICLE; ATTRIBUTABLE RISK; BEHAVIOR CHANGE; CIGARETTE SMOKING; COHORT ANALYSIS; CONTROLLED STUDY; ETHNICITY; FEMALE; FOLLOW UP; HEALTH SURVEY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROPENSITY SCORE; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 85049376940     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djx240     Document Type: Article

References (40)

1. U.S. Department of Health and Human Services. The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014. Printed with corrections, January 2014. Accessed June 2017.
2. Messer K, Trinidad DR, Al-Delaimy WK, et al. Smoking cessation rates in the United States: A comparison of young adult and older smokers. Am J Public Health. 2008;98(2):317-322.
3. Cahill K, Stevens S, Perera R, et al. Pharmacological interventions for smoking cessation: An overview and network meta-analysis. Cochrane Database Syst Rev. 2013;(5):CD009329.
4. Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update: A US public health service report. Am J Prevent Med. 2008;35(2):158-176.
5. Anderson JE, Jorenby DE, Scott WJ, et al. Treating tobacco use and dependence: An evidence-based clinical practice guideline for tobacco cessation. CHEST J. 2002;121(3):932-941.
6. Emery S, Kim Y, Choi YK, et al. The effects of smoking-related television advertising on smoking and intentions to quit among adults in the United States: 1999-2007. Am J Public Health. 2012;102(4):751-757.
7. Zhu S-H, Cummins SE, Gamst AC, et al. Quitting smoking before and after varenicline: A population study based on two representative samples of US smokers. Tobacco Control. 2016;25:464-469.
8. Zhu S-H, Lee M, Zhuang Y-L, et al. Interventions to increase smoking cessation at the population level: How much progress has been made in the last two decades? Tobacco Control. 2012;21(2):110-118.
9. Pierce JP, Gilpin EA. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA. 2002;288(10):1260-1264.
10. Alberg AJ, Patnaik JL, May JW, et al. Nicotine replacement therapy use among a cohort of smokers. J Addict Dis. 2005;24(1):101-113.
11. Kasza KA, Hyland AJ, Borland R, et al. Effectiveness of stop-smoking medications: Findings from the International Tobacco Control (ITC) Four Country Survey. Addiction. 2013;108(1):193-202.
12. Bareinboim E, Pearl J. A general algorithm for deciding transportability of experimental results. J Causal Interfer. 2013;1(1):107-134.
13. Stuart EA, Cole SR, Bradshaw CP, et al. The use of propensity scores to assess the generalizability of results from randomized trials. J Royal Stat Soc Ser A. 2011;174(2):369-386.
14. Pearl J. Generalizing experimental findings. J Causal Interfer. 2015;3(2): 259-266.
15. West R, Zhou X. Is nicotine replacement therapy for smoking cessation effective in the “real world”? Findings from a prospective multinational cohort study. Thorax. 2007;62(11):998-1002.
16. Greenland S. Causation and Causal Inference. Heidelberg, Germany: Springer Berlin Heidelberg; 2011.
17. Hernan MA, Robins JM. Estimating causal effects from epidemiological data. J Epidemiol Comm Health. 2006;60(7):578-586.
18. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011; 46(3):399-424.
19. Ho DE, Imai K, King G, et al. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Polit Anal. 2007; 15(3):199-236.
20. US Bureau of the Census. Current Population Survey: Design and Methodology. US Department of Commerce, Bureau of the Census; 2000.
21. US Department of Commerce, Census Bureau. The Tobacco Use Supplement to the Current Population Survey (TUS-CPS). Bethesda, MD: National Cancer Institute and Centers for Disease Control and Prevention. 2016. 22 June 2017. https://cancercontrol.cancer.gov/brp/tcrb/tus-cps/.
22. US Department of Commerce, Census Bureau. The Tobacco Use Supplement to the Current Population Survey June 2001, November 2001, and February 2002: Technical Documentation CPS-02, 2002. Bethesda, MD: National Cancer Institute and Centers for Disease Control and Prevention. 2002. 22 June 2017. https://thedataweb.rm.census.gov/ftp/cps_ftp.html#cpssupps.
23. US Department of Commerce, Census Bureau. The Tobacco Use Supplement to the Current Population Survey May 2010: Technical Documentation, 2010. Bethesda, MD: National Cancer Institute and Centers for Disease Control and Prevention. 2010. 22 June 2017. https://thedataweb.rm.census.gov/ftp/cps_ftp.html#cpssupps.
24. Davis WW, Hartman AM, Gibson JT. Weighting the Overlap Sample Obtained From Two Tobacco Use Supplements to the Current Population Survey. Bethesda, MD: National Cancer Institute; 2007. https://cancercontrol.cancer.gov/brp/tcrb/tus-cps/TUS-CPS_overlap.pdf?file=/studies/tus-cps/TUS-CPS_overlap.pdf.
25. US Department of Commerce, Census Bureau. The Tobacco Use Supplement to the Current Population Survey May 2010-May 2011: Technical Documentation, 2011. Bethesda, MD: National Cancer Institute and Centers for Disease Control and Prevention. 2011. 22 June 2017. https://www2.census.gov/programs-surveys/cps/techdocs/cpsmay10-11.pdf.
26. Baker TB, Piper ME, McCarthy DE, et al. Time to first cigarette in the morning as an index of ability to quit smoking: Implications for nicotine dependence. Nicotine Tobacco Res. 2007;9(suppl 4):S555-S570.
27. Bandura A. Self-efficacy: The Exercise of Control. Macmillan; 1997.
28. Yao XI, Wang X, Speicher PJ, et al. Reporting and guidelines in propensity score analysis: A systematic review of cancer and cancer surgical studies. J Natl Cancer Inst. 2017;109(8):djw323.
29. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: A Monte Carlo study. Stat Med. 2007;26(4): 734-753.
30. Smith HL. Matching with multiple controls to estimate treatment effects in observational studies. Sociol Methodol. 1997;27(1):325-353.
31. King G, Tomz M, Wittenberg J. Making the most of statistical analyses: Improving interpretation and presentation. Am J Polit Sci. 2000;44(2):347-361.
32. Motschman CA, Gass JC, Wray JM, et al. Selection criteria limit generalizability of smoking pharmacotherapy studies differentially across clinical trials and laboratory studies: A systematic review on varenicline. Drug Alcohol Depend. 2016;169:180-189.
33. Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): A double-blind, rando-mised, placebo-controlled clinical trial. Lancet. 2016;387(10037): 2507-2520.
34. Preventive Services Task Force US. Counseling and interventions to prevent tobacco use and tobacco-caused disease in adults and pregnant women: US Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2009;150(8):551.
35. Baker TB, Piper ME, Stein JH, et al. Effects of nicotine patch vs varenicline vs combination nicotine replacement therapy on smoking cessation at 26 weeks: A randomized clinical trial. JAMA. 2016;315(4):371-379.
36. Stead LF, Perera R, Lancaster T. Telephone counselling for smoking cessation. Cochrane Database Syst Rev. 2013;(8):CD002850.
37. Zhu S-H, Anderson CM, Cummins SE, et al. Incentives for helping Medicaid recipients quit smoking: A randomized controlled trial. Abstract 51. Ann Behav Med. 2017:S1732-S1733.
38. Keller PA, Schillo BA, Kerr AN, et al. Increasing reach by offering choices: Results from an innovative model for statewide services for smoking cessation. Prevent Med. 2016;91:96-102.
39. Gilpin EA, Pierce JP, Farkas AJ. Duration of smoking abstinence and success in quitting. J Natl Cancer Inst. 1997;89(8):572.
40. West R, Raw M, McNeill A, et al. Health-care interventions to promote and assist tobacco cessation: A review of efficacy, effectiveness and affordability for use in national guideline development. Addiction. 2015;110(9):1388-1403.